TOP HEADLINES

Featured Story

  • GSK taps Slaoui to chair flat-selling vaccines unit with an eye to the future

    GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.

Novavax nabs FDA fast-track tag as search for H7N9 vaccine continues

Right now, the U.S. government is in search of an H7N9 vaccine that can reach the market to help prevent against a potential pandemic. And a new FDA fast-track designation for Novavax's candidate might help it get there a little sooner.

South African trial renews hopes in failed HIV vaccine combo

An HIV vaccine regimen that failed in a notable clinical trial conducted in Thailand has been given a new chance to prove itself.

Dendreon's Provenge at the center of CMS insider trading probe

The SEC is investigating whether officials at the Center for Medicare and Medicaid Services tipped off a policy research group about the agency's review of Dendreon's cancer vaccine, Provenge, The Wall Street Journal reports.

Brand-new Affinivax takes aim at Pfizer's Prevnar with next-gen conjugate vax tech

In conventional conjugate vaccines, proteins act as carriers for polysaccharides that induce an immune response. But what if those proteins could induce an immune response, too?

Ebola update: Novavax testing nanoparticle jab, Glaxo gets EMA's advice

With several companies now expediting Ebola vaccines in an attempt to halt the spread of the deadly virus, Novavax has jumped in the race, announcing that it's using its nanoparticle vaccine technology to advance a candidate of its own.

MORE NEWS

From Our Sister Sites

FierceBiotech

A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.

FierceBiotech

In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of antibiotic R&D with the goal of making antibiotic R&D economically attractive again. And more.